CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...
At CTS, we understand the impact converting to the Ortho viral marker platform has on your operation...
Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA test...
TEMPE, Ariz. (Sept. 8, 2022) — Marion Lanteri, Ph.D., began this week as Creative Testing Solu...
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...